The outbreak of the coronavirus epidemic has brought a huge threat to human health. Due to the highly contagious and pathogenic nature of this virus to humans, handling coronavirus must be conducted within high-containment facilities such as biosafety level (BSL) 3 or 4 laboratories, thus hampering drug discovery of anti-COVID-19. Aubrak has developed proprietary in vitro anti-COVID-19 drug screening models, which can advance the discovery of viral entry and pathological process inhibitors. Such inhibitors would be applied in both prophylaxis and therapeutics.